

# Ileal Sodium/Bile Acid Cotransporter - Pipeline Review, H2 2019

<https://marketpublishers.com/r/IA854B27EAFDEN.html>

Date: December 2019

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: IA854B27EAFDEN

## Abstracts

Ileal Sodium/Bile Acid Cotransporter - Pipeline Review, H2 2019

### SUMMARY

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Ileal Sodium/Bile Acid Co-transporter is encoded by SLC10A2 gene. It plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine and cholesterol metabolism.

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Dermatology and Genetic Disorders which include indications Cholestasis, Primary Sclerosing Cholangitis, Alagille Syndrome, Biliary Atresia, Non-Alcoholic Steatohepatitis (NASH), Progressive Familial Intrahepatic Cholestasis, Pruritus, Non Alcoholic Fatty Liver Disease (NAFLD) and Primary Biliary Cholangitis (Primary Biliary Cirrhosis).

The latest report Ileal Sodium/Bile Acid Cotransporter - Pipeline Review, H2 2019, outlays comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics, complete with analysis by indications, stage of development,

mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects

The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid

Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development

Albireo Pharma Inc

GlaxoSmithKline Plc

Mirum Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles

Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elobixibat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linerixibat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

maralixibat chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odevixibat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-435 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volixibat potassium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Discontinued Products

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones

Featured News & Press Releases

Dec 16, 2019: Mirum Pharmaceuticals completes successful pre-NDA meeting with FDA for Maralixibat

Nov 08, 2019: Mirum Pharmaceuticals presents data demonstrating long-term durability of treatment effect of Maralixibat in children with cholestatic liver diseases

Oct 28, 2019: Mirum Pharmaceuticals announces Breakthrough Therapy Designation for Maralixibat for the treatment of pruritus associated with Alagille syndrome

Oct 21, 2019: Durability of treatment effect of Mirum Pharmaceuticals Maralixibat for children with Alagille syndrome featured in late breaking session at the Liver Meeting 2019

Oct 01, 2019: Mirum Pharmaceuticals to present new data on Volixibat Potassium at

## The Liver Meeting 2019

Oct 01, 2019: Mirum Pharmaceuticals to present new data on Maralixibat Chloride at The Liver Meeting 2019

Sep 30, 2019: Albireo announces presentations at NASPGHAN 2019 Annual Meeting

Jul 09, 2019: Albireo provides clinical development update on elobixibat

Jul 09, 2019: Albireo provides clinical development update for odevixibat

Jul 09, 2019: Mirum Pharmaceuticals initiates phase 3 clinical trial for pediatric patients with progressive familial intrahepatic cholestasis

Jun 07, 2019: Data on Albireo's odevixibat presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

May 23, 2019: Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting

Apr 15, 2019: Albireo to assess elobixibat in Phase II trial for liver diseases

Apr 15, 2019: Mirum Pharmaceuticals presented data on Volixibat at The International Liver Congress 2019

Apr 15, 2019: Mirum Pharmaceuticals presented new data demonstrating durable improvements in clinical outcome measures in patients with PFIC2 and Alagille syndrome treated with Maralixibat

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Albireo Pharma Inc, H2 2019  
Pipeline by GlaxoSmithKline Plc, H2 2019  
Pipeline by Mirum Pharmaceuticals Inc, H2 2019  
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019  
Dormant Projects, H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

### COMPANIES MENTIONED

Albireo Pharma Inc

GlaxoSmithKline Plc

Mirum Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

## I would like to order

Product name: Ileal SodiumBile Acid Cotransporter - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/IA854B27EAFDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA854B27EAFDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970